JP2022554258A5 - - Google Patents
Info
- Publication number
- JP2022554258A5 JP2022554258A5 JP2022525050A JP2022525050A JP2022554258A5 JP 2022554258 A5 JP2022554258 A5 JP 2022554258A5 JP 2022525050 A JP2022525050 A JP 2022525050A JP 2022525050 A JP2022525050 A JP 2022525050A JP 2022554258 A5 JP2022554258 A5 JP 2022554258A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- cancer
- alk
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201915618A GB201915618D0 (en) | 2019-10-28 | 2019-10-28 | ALK inhibitors for treatment of ALK-negative cancer and antibody-mediated diseases |
| GB1915618.1 | 2019-10-28 | ||
| PCT/EP2020/056698 WO2021083555A1 (en) | 2019-10-28 | 2020-03-12 | Alk inhibitors for treatment of alk-negative cancer and plasma cell-mediated diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022554258A JP2022554258A (ja) | 2022-12-28 |
| JP2022554258A5 true JP2022554258A5 (https=) | 2023-03-15 |
| JP7629228B2 JP7629228B2 (ja) | 2025-02-13 |
Family
ID=68768829
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022525050A Active JP7629228B2 (ja) | 2019-10-28 | 2020-03-12 | Ａｌｋ陰性癌および形質細胞媒介性疾患の治療のためのａｌｋ阻害剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12465607B2 (https=) |
| EP (1) | EP4051288A1 (https=) |
| JP (1) | JP7629228B2 (https=) |
| KR (1) | KR102946955B1 (https=) |
| CN (1) | CN114901289A (https=) |
| AU (1) | AU2020374150B2 (https=) |
| CA (1) | CA3159339A1 (https=) |
| GB (1) | GB201915618D0 (https=) |
| WO (1) | WO2021083555A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230091284A (ko) * | 2021-12-16 | 2023-06-23 | 부산대학교 산학협력단 | Surf4 억제제를 포함하는 혈액암의 예방 또는 치료용 약학적 조성물 |
| WO2024017334A1 (zh) * | 2022-07-22 | 2024-01-25 | 贝达药业股份有限公司 | 用于rdaa阳性疾病的诊断和治疗的方法和试剂盒 |
| CN115993453B (zh) * | 2022-07-22 | 2025-03-25 | 四川大学 | 用于rdaa阳性疾病的诊断和治疗的方法和试剂盒 |
| WO2024059525A2 (en) * | 2022-09-12 | 2024-03-21 | Endotarget, Inc. | Compounds and methods for the targeted degradation of anaplastic lymphoma kinase and ros1 kinase |
| KR20250160958A (ko) * | 2023-03-22 | 2025-11-14 | 어센테지 파마 (쑤저우) 컴퍼니 리미티드 | 약학적 조합 및 이의 응용 |
| CN119700981A (zh) * | 2024-12-24 | 2025-03-28 | 中南大学湘雅二医院 | Alk/ltk抑制剂在制备治疗和/或预防慢性淋巴细胞白血病的产品中的应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA017405B9 (ru) | 2006-12-08 | 2014-05-30 | АйАрЭм ЭлЭлСи | Соединения и композиции в качестве ингибиторов протеинкиназы |
| AU2009233963B2 (en) | 2008-04-07 | 2011-10-06 | Irm Llc | Compounds and compositions as kinase inhibitors |
| US8904383B2 (en) | 2008-04-10 | 2014-12-02 | Hewlett-Packard Development Company, L.P. | Virtual machine migration according to environmental data |
| PE20100087A1 (es) | 2008-06-25 | 2010-02-08 | Irm Llc | Compuestos y composiciones como inhibidores de cinasa |
| BR112013015000A2 (pt) | 2010-12-17 | 2016-08-09 | Novartis Ag | formas cristalinas de 5-cloron2-(2-isopropóxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propano-2-sulfonil)-fenil]-pirimidina-2,4-diamina |
| EP2916841A1 (en) | 2012-11-07 | 2015-09-16 | Novartis AG | Combination therapy |
| US10117872B2 (en) | 2014-03-28 | 2018-11-06 | Università Degli Studi Di Genova | Tyrosine kinase inhibitors for use in a method of treating cancer in association with a reduced caloric intake |
| CN105294649B (zh) | 2014-07-30 | 2019-05-14 | 江苏奥赛康药业股份有限公司 | 一种Ceritinib化合物及其药物组合物 |
| US10695426B2 (en) * | 2014-08-25 | 2020-06-30 | Pfizer Inc. | Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer |
| KR20170060042A (ko) * | 2014-09-13 | 2017-05-31 | 노파르티스 아게 | Alk 억제제의 조합 요법 |
| CN105622577A (zh) * | 2014-11-29 | 2016-06-01 | 江苏先声药业有限公司 | 一种色瑞替尼的新晶型及其制备方法 |
| WO2016098070A1 (en) | 2014-12-19 | 2016-06-23 | Novartis Ag | Crystalline form of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine |
| WO2016098042A1 (en) | 2014-12-19 | 2016-06-23 | Novartis Ag | Use of ceritinib (ldk-378) in the treatment of fes or fer mediated disorders, in particular proliferative disorders |
| JP2018529719A (ja) * | 2015-09-30 | 2018-10-11 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | Ａｌｋ陰性がんを処置するためのｐｄ−１系結合アンタゴニストおよびａｌｋ阻害剤の組合せ |
| JPWO2019039390A1 (ja) | 2017-08-25 | 2020-07-30 | 国立大学法人東海国立大学機構 | 若年性骨髄単球性白血病治療薬 |
| WO2019113345A1 (en) | 2017-12-06 | 2019-06-13 | Spyro Mousses | Combination of cancer therapeutics for treatment of cancer and hyperproliferative diseases |
| CN110063956A (zh) * | 2018-01-20 | 2019-07-30 | 中国科学院上海药物研究所 | 治疗肝癌的药物组合和方法 |
-
2019
- 2019-10-28 GB GB201915618A patent/GB201915618D0/en not_active Ceased
-
2020
- 2020-03-12 CA CA3159339A patent/CA3159339A1/en active Pending
- 2020-03-12 JP JP2022525050A patent/JP7629228B2/ja active Active
- 2020-03-12 AU AU2020374150A patent/AU2020374150B2/en active Active
- 2020-03-12 US US17/772,192 patent/US12465607B2/en active Active
- 2020-03-12 KR KR1020227018050A patent/KR102946955B1/ko active Active
- 2020-03-12 WO PCT/EP2020/056698 patent/WO2021083555A1/en not_active Ceased
- 2020-03-12 EP EP20711156.8A patent/EP4051288A1/en active Pending
- 2020-03-12 CN CN202080089754.2A patent/CN114901289A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022554258A5 (https=) | ||
| Antoniou et al. | Genital HPV Lesions and Molluscum Contagiosum Occurring in Patients Receiving Anti-TNF-[alpha] Therapy | |
| BR112013012854B1 (pt) | Composições farmacêuticas compreendendo inibidores de bcl-2 seletivos | |
| JP2019503365A5 (https=) | ||
| MX2013010217A (es) | Uso de 3 - (5 - amino - 2 - metil - 4 - oxoquinazolin - 3 (4h) - il) piperidin - 2, 6 - diona en tratamiento de enfermedades inmunorrelacionadas e inflamatorias. | |
| EP3868403A1 (en) | Taci-fc fusion protein and use thereof | |
| JP2020528455A5 (https=) | ||
| US20220142977A1 (en) | Methods of treating conditions related to the s1p1 receptor | |
| JP2008536855A5 (https=) | ||
| JP2020522549A5 (https=) | ||
| JP2015172060A5 (https=) | ||
| Mariette et al. | OP0135 Safety and Efficacy of subcutaneous belimumab and intravenous rituximab combination in patients with primary sjögren's syndrome: a phase 2, randomised, placebo-controlled 68-week study | |
| JP2015517511A5 (https=) | ||
| Niebel et al. | Successful treatment of psoriatic arthritis and comorbid annular atrophic lichen planus with etanercept | |
| Langer et al. | Successful therapy of acrodermatitis continua of Hallopeau with IL‐23 blockers–two new cases | |
| Zhang et al. | Similarities and differences between spondyloarthritis in Asia and other parts of the world | |
| CN104873515B (zh) | 依鲁替尼对flt3‑itd突变的急性白血病的应用 | |
| JP2022523018A5 (https=) | ||
| WO2020054821A1 (ja) | ジスルフィラムを含むグループ２自然リンパ球（ｉｌｃ２）の活性抑制剤 | |
| Akarsu | How should we do in the selection and follow-up of systemic conventional treatments in psoriasis? | |
| JP2022512158A5 (https=) | ||
| Bisaccia et al. | Extracorporeal photochemotherapy for the treatment of refractory Crohn’s disease | |
| Smith et al. | Novel pharmaceuticals and therapeutics for tumor necrosis factor-alpha-resistant Crohn's disease: A narrative review | |
| CN115038445A (zh) | 用于治疗炎性疾病的新型药物 | |
| Li et al. | OP0206 EFFICACY AND SAFETY OF GENAKUMAB IN ACTIVE SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (sJIA): A MULTICENTER, RANDOMIZED, OPEN-LABEL PHASE 2 CLINICAL STUDY |